Abstracts tagged "radiography and tumor necrosis factor (TNF)"

Abstract Number: 702 • 2018 ACR/ARHP Annual Meeting
Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Dongze Wu¹, Priscilla Wong¹, James F Griffith², Jiang Yue¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Psoriatic arthritis (PsA) often leads to structural damage with resultant disability and reduced quality of life. Biologic disease modifying anti-rheumatic drugs (bDMARDs), including tumor…
Abstract Number: 1540 • 2017 ACR/ARHP Annual Meeting
Comparison of Radiologic Parameters of Ankylosing Spondylitis Treated with Anti-TNF-α Versus Non-Steroidal Anti-Inflammatory Drugs and Sulfasalazine
Seung Min Son, Orthopaedic surgery, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of (South)
Background/Purpose: There are many studies about impact of TNF-inhibitors on radiographic progression but little data are available on the relationship between treatment agents and sagittal…
Abstract Number: 2567 • 2014 ACR/ARHP Annual Meeting
Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab
Xenofon Baraliakos¹, Kay-Geert A. Hermann², Stephen Xu³, Benjamin Hsu³ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Janssen Research & Development, LLC., Spring House, PA
Background/Purpose Using data from GO-RAISE, we analyzed correlations between serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels, radiographic progression and inflammation as…
Abstract Number: 782 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis
Nigil Haroon¹, Robert D. Inman², Thomas J. Learch³, Michael H. Weisman⁴, Michael M. Ward⁵, John D. Reveille⁶ and Lianne S. Gensler⁷, ¹Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Cedars-Sinai, Los Angeles, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁶Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The influence of anti-TNF therapy on radiographic progression in ankylosing spondylitis (AS) is not well established. We studied this effect on radiographic progression in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].